nan
Acrylic Brochure Box Outdoor Market Size Outlook: How Fast Will Revenue Grow Through 2030?
The cell and gene therapy bio-manufacturing market size has witnessed substantial growth in recent years. This market is projected to expand from $12.35 billion in 2025 to $13.83 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 12.0%. Historically, this expansion is largely attributed to several factors, including the swift advancement in monoclonal antibody and biologics development, increased investment in early gene therapy research, the expansion of biotechnology manufacturing infrastructure, the rising prevalence of chronic and genetic diseases, and the establishment of regulatory frameworks for advanced therapies.
The cell and gene therapy bio-manufacturing market is expected to experience substantial growth over the next few years, projected to reach $21.46 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.6%. This forecasted expansion is attributed to the increasing commercialization of gene and cell therapies, a growing demand for scalable viral vector production, the wider adoption of personalized medicine, the expansion of contract development and manufacturing organizations, and the rising automation and digitalization of biomanufacturing facilities. Key trends anticipated in this period include a greater embrace of single-use bioprocessing systems in cell therapy manufacturing, an increasing need for automated and closed-system cell processing platforms, the advanced use of viral vector production technologies, the broadening of personalized and autologous therapy manufacturing pipelines, and a deeper integration of digital biomanufacturing with data-driven quality control.
Download A Free Sample Report For Comprehensive Market Insights:
Cell And Gene Therapy Bio-Manufacturing Market Growth Drivers: What Factors Are Accelerating Expansion?
The anticipated acceleration of the cell and gene therapy bio-manufacturing market is linked to the swift rise in cell and gene therapy approvals. These therapies are advanced medical treatments employing modified cells or genetic material to treat, prevent, or potentially cure diseases, including cancer, rare genetic disorders, and chronic conditions. The increase in approvals for cell and gene therapies primarily stems from rapid advancements in genetic engineering technologies such as CRISPR, a deeper understanding of disease biology, and enhanced delivery systems that enable safer and more effective targeted treatments. Such approvals stimulate cell and gene therapy bio-manufacturing by boosting investment, expanding production infrastructure, and fostering the creation of standardized, high-quality, and regulatory-compliant manufacturing processes essential for consistently producing safe and effective therapies for clinical and commercial use. For instance, in January 2024, according to the American Society of Gene and Cell Therapy, a US-based organization for gene and cell therapy, the fourth quarter of 2023 observed a 10% increase in the number of gene therapies in Phase III compared to the previous quarter, marking the first rise since the third quarter of 2022. Ultimately, the rapid growth in cell and gene therapy approvals is driving the growth of the cell and gene therapy market.
Acrylic Brochure Box Outdoor Market Segmentation: How Is The Market Structured Across Key Categories?
The cell and gene therapy bio-manufacturing market covered in this report is segmented –
1) By Product Type: Bioreactors And Fermenters; Cell Processing Systems; Viral Vector Production Systems; Consumables And Reagents; Software And Automation Platforms
2) By Technology: Viral Vector Based Manufacturing; Non Viral Gene Delivery Systems; Autologous Cell Therapy Production; Allogeneic Cell Therapy Production; Stem Cell Based Manufacturing
3) By Application: Upstream Processing; Harvesting; Downstream Processing
4) By End User: Pharmaceutical And Biotechnology Companies; Contract Development And Manufacturing Organizations; Academic And Research Institutes; Hospitals And Clinical Centers
Subsegments:
1) By Bioreactors And Fermenters: Single Use Bioreactors; Stainless Steel Bioreactors; Stirred Tank Bioreactors; Wave Induced Bioreactors; Perfusion Bioreactors; Continuous Fermentation Systems
2) By Cell Processing Systems: Cell Isolation Systems; Cell Expansion Systems; Cell Washing Systems; Cell Separation Systems; Automated Cell Processing Platforms; Closed System Cell Processing Equipment
3) By Viral Vector Production Systems: Lentiviral Vector Production Systems; Adeno Associated Viral Vector Production Systems; Retroviral Vector Production Systems; Baculovirus Expression Systems; Transfection Systems; Viral Vector Purification Systems
4) By Consumables And Reagents: Cell Culture Media; Buffers And Solutions; Filtration Consumables; Chromatography Resins; Single Use Bags And Tubing; Assay And Detection Reagents
5) By Software And Automation Platforms: Manufacturing Execution Software; Laboratory Information Management Software; Process Monitoring Platforms; Data Analytics Platforms; Workflow Automation Systems; Quality Control Software
Technological Advancements In Standardized Viral Vector Manufacturing Platforms For Cell And Gene Therapy Production
Major companies operating in the cell and gene therapy bio-manufacturing market are focusing on developing innovation systems, such as modular lentiviral vector manufacturing systems, to enhance scalability, reduce development timelines, and improve consistency in clinical and commercial production of advanced therapies. Modular lentiviral vector manufacturing systems are standardized, scalable platforms that use predefined production modules to manufacture lentiviral vectors under GMP conditions, helping improve consistency, reduce variability, and accelerate development from research to clinical and commercial production. For instance, in May 2026, Andelyn Biosciences, a US-based contract development and manufacturing organization (CDMO), launched its LVV Curator platform, a standardized lentiviral vector manufacturing system designed to streamline cell and gene therapy production. The platform leverages a modular and pre-validated framework built on proven Curator methodology that has supported over 100 adeno-associated virus (AAV) programs, enabling faster development and reduced process risk. It is designed to industrialize lentiviral vector processes from concept to clinic, improving scalability, productivity, and product purity while minimizing development complexity.
Cell And Gene Therapy Bio-Manufacturing Market Key Players And Strategic Industry Positioning
Major companies operating in the cell and gene therapy bio-manufacturing market are Thermo Fisher Scientific Inc.; Merck KGaA; Lonza Group AG; Samsung Biologics Co. Ltd.; Danaher Corporation; FUJIFILM Corporation; Pfizer CentreOne; Charles River Laboratories International Inc.; Boehringer Ingelheim International GmbH; Sartorius AG; Miltenyi Biotec B.V. & Co. KG; AGC Biologics LLC; Oxford Biomedica plc; Takara Bio Inc.; KBI Biopharma Inc.; Rentschler Biopharma SE; Minaris Regenerative Medicine GmbH; ElevateBio LLC; Forge Biologics Holdings LLC; Porton Advanced Solutions Co. Ltd.; Cellares Corporation; Repligen Corporation; Asahi Kasei Medical; Thermo Fisher Scientific / Brammer Bio; WuXi Advanced Therapies; Catalent Inc.
Access The Complete Cell And Gene Therapy Bio-Manufacturing Market Report:
Cell And Gene Therapy Bio-Manufacturing Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the cell and gene therapy bio-manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy bio-manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.